First Tracks Biotherapeutics, Inc. (TRAX)
| Market Cap | 1.49B |
| Revenue (ttm) | n/a |
| Net Income | -160.30M |
| EPS | -4.53 |
| Shares Out | 35.73M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 525,530 |
| Open | 39.45 |
| Previous Close | 40.46 |
| Day's Range | 39.20 - 43.78 |
| 52-Week Range | 14.72 - 49.91 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 69.44 (+66.4%) |
| Earnings Date | Aug 12, 2026 |
About TRAX
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti‑CD122 antagonist that targets the shared beta subunit of the IL‑15 and IL‑2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2‑modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). Fir... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for TRAX stock is "Strong Buy." The 12-month stock price target is $69.44, which is an increase of 66.40% from the latest price.
News
First Tracks Biotherapeutics Announces Participation in September Investor Conferences
SAN DIEGO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways imp...
First Tracks Biotherapeutics reports Q2 EPS (95c), consensus (80c)
“First Tracks continues to execute against a broad development strategy for our potentially best-in-class CD122 antagonist, ANB033, and anticipates treating patients across four indications in 2027. W...
First Tracks Biotherapeutics price target raised to $65 from $48 at Barclays
Barclays raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $65 from $48 and keeps an Overweight rating on the shares post the Q2 report. The company reiterates…
First Tracks price target raised to $57 from $44 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $57 from $44 and keeps a Buy rating on the shares following the Q2 report. The firm…
First Tracks Biotherapeutics price target raised to $95 from $54 at Piper Sandler
Piper Sandler raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $95 from $54 based on competitor clinical validation of anti-CD122 mechanism of action, while keeping an Overweig...
First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways imp...
First Tracks Biotherapeutics Earnings release: Q2 2026
First Tracks Biotherapeutics released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
First Tracks Biotherapeutics Quarterly report: Q2 2026
First Tracks Biotherapeutics has published its Q2 2026 quarterly earnings report on August 12, 2026.
First Tracks Biotherapeutics management to meet with Piper Sandler
Meeting to be held on August 17-18 hosted by Piper Sandler.
First Tracks Biotherapeutics price target raised to $65 from $45 at UBS
UBS raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $65 from $45 and keeps a Buy rating on the shares.
First Tracks Biotherapeutics price target raised to $60 from $30 at Wedbush
Wedbush raised the firm’s price target on First Tracks Biotherapeutics to $60 from $30 and keeps an Outperform rating on the shares. Relevant for First Tracks Biotherapeutics (TRAX), Argenx (ARGX)…
First Tracks Biotherapeutics price target raised to $55 from $30 at Wells Fargo
Wells Fargo analyst Derek Archila raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $55 from $30 and keeps an Overweight rating on the shares. The firm says…
First Tracks Biotherapeutics price target raised to $48 from $40 at Barclays
Barclays raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $48 from $40 and keeps an Overweight rating on the shares. The firm has increased conviction in ANB033…
First Tracks Biotherapeutics price target raised to $44 from $30 at H.C. Wainwright
H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $44 from $30 and keeps a Buy rating on the shares after competitor Forte…
First Tracks Biotherapeutics initiated with an Overweight at Wells Fargo
Wells Fargo analyst Derek Archila initiated coverage of First Tracks Biotherapeutics (TRAX) with an Overweight rating and $30 price target At current share levels, the Street undervalues both ANB033’s...
First Tracks Biotherapeutics Transcript: Jefferies Global Healthcare Conference 2026
A newly independent biotech with $180 million in cash is advancing a pipeline of antibody therapies for autoimmune diseases, led by ANB033 targeting CD122. Key phase I-B trials in celiac disease and EoE are ongoing, with major data readouts expected in Q4 and mid-2027.
First Tracks Biotherapeutics Slides: FY 2026
First Tracks Biotherapeutics has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 3, 2026.
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
SAN DIEGO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathw...
First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways impl...
First Tracks Biotherapeutics Earnings release: Q1 2026
First Tracks Biotherapeutics released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
First Tracks Biotherapeutics Quarterly report: Q1 2026
First Tracks Biotherapeutics has published its Q1 2026 quarterly earnings report on May 14, 2026.
First Tracks Biotherapeutics Slides: Corporate presentation
First Tracks Biotherapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 14, 2026.
First Tracks Biotherapeutics files to sell 10.5M shares of common for holders
16:38 EDT First Tracks Biotherapeutics (TRAX) files to sell 10.5M shares of common for holders
First Tracks Biotherapeutics Registration statement: Registration filing
First Tracks Biotherapeutics filed a registration statement on May 8, 2026, providing details about a securities offering with the SEC.
First Tracks Biotherapeutics initiated with an Overweight at Piper Sandler
Piper Sandler analyst Yasmeen Rahimi initiated coverage of First Tracks Biotherapeutics (TRAX) with an Overweight rating and $54 price target The company has a “differentiated pipeline” across ANB033,...